Now Accepting Walk-In Visits

We Are Here to Help

At NW Indiana ER & Hospital, our top priority is ensuring the safety of those we serve. We are committed to the cleanliness of our hospital and to providing an environment that is safe for our patients and our medical team.

We are working collaboratively with the Indiana Department of Health and other health facilities to address the growing concern of COVID-19. Please review our evaluation hours below. If you have any questions, please contact us at 219-554-9911.

Emergency COVID-19 Evaluation Procedures

If you feel you’ve had exposure to COVID-19 or you’re experiencing symptoms related to COVID-19 such as,

shortness of breath, cough, fever/chills, muscle/body aches, headache, and more,

emergency COVID-19 evaluations are available with results within 30 minutes.

Emergency COVID-19 evaluations are conducted through our emergency room by a board-certified ER physician.

Emergency room charges apply to those without a written order from a staff physician.

All commercial insurances are accepted with a $0 upfront cost.

At this time, due to federal law, we’re unable to accept Medicare & Medicaid plans for emergency COVID-19 evaluations.

If you are without insurance, we also have affordable pricing options available here.

Testing hours: 7:15 AM – 10:00 PM

Available Evaluation: *Rapid Nasal Swab, PCR, Molecular RNA

*Antibody Blood Test

Coronavirus Hotline: 1-855-600-3453

**All patients without a written order from a staff physician will be seen through the emergency room after a free medical screening (emergency room charges will apply)

*This test has not been FDA cleared or approved; This test has been authorized by FDA under an EUA for use by authorized laboratories; This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.